Physician profile
Robert T Chambers
NPI 1619911039
$7,571.33
in general payments reported to CMS, 2019-2025
38 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $1,039 · 2021: $717 · 2022: $707 · 2023: $1,414 · 2024: $1,299 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,880.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,218.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $960.23 | 2019-2025 | |
| Abbvie INC. | $910.70 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $823.95 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $687.51 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $325.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $227.89 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.56 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $207.44 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $174.38 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $165.47 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $152.49 | 2019-2025 | Airsupra, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $138.58 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.34 | 2019-2023 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $115.81 | 2019-2023 | Eliquis |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.